We are live on ! Find out more

CNXU

Conexeu Sciences Inc

CNXU

Market cap $125M

4.68 USD

-0.29

5.84%

At close Updated Sep 8, 4:00 PM EDT

Pre-market

After hours

4.67

-0.01

0.21%

1 day

-5.84%

5 days

-34.18%

1 month

-35.63%

3 months

-69.35%

6 months

-64.19%

Year to date

-64.19%

1 year

-64.19%

5 years

-64.19%

10 years

-64.19%

About: Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 12.5%

Neutral 87.5%

Negative 0%

Conexeu Sciences Sets September and October 2026 Conference Schedule

RENO, Nev., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) (“Conexeu” or the “Company”), a preclinical-stage biotechnology company advancing an investigational tissue-restoration platform, is pleased to announce its participation in the following investor and industry conferences during September and October 2026.

Conexeu Sciences Sets September and October 2026 Conference Schedule

Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration

Peer-reviewed research points to the extracellular matrix, the framework that holds tissue together, as central to that work. More than a decade of research has gone into Conexeu's CXU™ Platform

Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration

The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It

Highlights An unclaimed opportunity. Large-volume body contouring, and restoration of the breasts, hips, and buttocks is a significant injectable aesthetics category yet to be claimed.

The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It

A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today's Injectables Were Not Built to Fill

Study Highlights P.R.O.O.F study complete, marking an important catalyst. Conexeu has completed its P.R.O.O.F (Performance and Regeneration Outcomes of Flowable Collagen) preclinical program, which provides the evidence base behind the CXU™ platform's development direction and the Company's planned move into the medical aesthetics injectable market.

A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today's Injectables Were Not Built to Fill

Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform

Nasdaq-Listed Biotech Pioneer Among the First Companies to Operate at adMare's New M4 Innovation Centre Nasdaq-Listed Biotech Pioneer Among the First Companies to Operate at adMare's New M4 Innovation Centre

Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform

Conexeu Sciences: Hanging On The FDA 510(k) Pathway Submission

Conexeu Sciences is rated Buy, leveraging a patented CXU platform targeting multi-billion-dollar regenerative medicine markets with a flagship wound care product. CNXU's Ten-Minute Tissue™ aims for FDA 510(k) clearance by Q1 2027, potentially accelerating market entry to late 2027 and minimizing investor dilution. Current valuation (~$13.20/share) exceeds risk-adjusted fair value ($10.71), but premium is justified by pipeline breadth and upside if regulatory milestones are met.

Conexeu Sciences: Hanging On The FDA 510(k) Pathway Submission

Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing

Board expansion from six to nine directors and the appointment of a Chief Commercial Officer and an advisory board member to help accelerate growth and strengthen execution Board expansion from six to nine directors and the appointment of a Chief Commercial Officer and an advisory board member to help accelerate growth and strengthen execution

Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing

Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program

Activities are intended to support regulatory testing and the Company's planned first-quarter 2027 FDA 510(k) premarket notification submission Activities are intended to support regulatory testing and the Company's planned first-quarter 2027 FDA 510(k) premarket notification submission

Conexeu Sciences Reports Manufacturing Scale Up and Regulatory Progress for Lead CXU™ Wound Care Program

Before the IPO: 4 Companies That Rewarded Investors Who Got In Early

The SpaceX NASDAQ: SPCX IPO is the most talked-about market event in years. But Chris Graebe, an analyst at Weiss Ratings, says the investors who will really profit already got in—and it wasn't recently.

Before the IPO: 4 Companies That Rewarded Investors Who Got In Early

Conexeu Sciences to Ring Nasdaq Bell on June 10, 2026

RENO, Nev., June 03, 2026 (GLOBE NEWSWIRE) -- Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a biotechnology company advancing tissue regeneration, will ring the Nasdaq Closing Bell on Wednesday, June 10, 2026, at the Nasdaq MarketSite in New York City in celebration of its recent public listing and the commencement of

Conexeu Sciences to Ring Nasdaq Bell on June 10, 2026

See News Rankings

Price charts implemented using Lightweight Charts™